Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.72
CAPS's Cash to Debt is ranked lower than
99.99% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. CAPS: 0.72 )
Ranked among companies with meaningful Cash to Debt only.
CAPS' s Cash to Debt Range Over the Past 10 Years
Min: 0.36  Med: 10000.00 Max: No Debt
Current: 0.72
F-Score: 2
Z-Score: -191.14
M-Score: -7.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -195.44
CAPS's ROE (%) is ranked lower than
99.99% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. CAPS: -195.44 )
Ranked among companies with meaningful ROE (%) only.
CAPS' s ROE (%) Range Over the Past 10 Years
Min: -86.35  Med: -36.77 Max: -15.71
Current: -195.44
-86.35
-15.71
ROA (%) -126.01
CAPS's ROA (%) is ranked lower than
99.99% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. CAPS: -126.01 )
Ranked among companies with meaningful ROA (%) only.
CAPS' s ROA (%) Range Over the Past 10 Years
Min: -77.87  Med: -32.56 Max: -15.03
Current: -126.01
-77.87
-15.03
ROC (Joel Greenblatt) (%) -1437.86
CAPS's ROC (Joel Greenblatt) (%) is ranked lower than
99.99% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. CAPS: -1437.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CAPS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7428.27  Med: -3655.16 Max: -910.87
Current: -1437.86
-7428.27
-910.87
EBITDA Growth (3Y)(%) -23.60
CAPS's EBITDA Growth (3Y)(%) is ranked lower than
99.99% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. CAPS: -23.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CAPS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -37.1  Med: -11.50 Max: 64.5
Current: -23.6
-37.1
64.5
EPS Growth (3Y)(%) -24.60
CAPS's EPS Growth (3Y)(%) is ranked lower than
99.99% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. CAPS: -24.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CAPS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -41.6  Med: -24.60 Max: 50.4
Current: -24.6
-41.6
50.4
» CAPS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with CAPS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:CPMD, NAS:VTGN, XCNQ:THC, XTAE:THXBY, NAS:BIND, XCNQ:VRT » details
Capstone Therapeutics Corp is a biotechnology company engaged in developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions.

Capstone Therapeutics Corp was incorporated as a Delaware corporation in July 1987 as IatroMed, Inc. On May 21, 2010 the name was changed to Capstone Therapeutics Corp. It is a biotechnology company which develops a pipeline of novel therapeutic peptides aimed at helping patients with under-served medical conditions. On August 3, 2012, it entered into a joint venture, LipimetiX Development, LLC, to develop Apo E mimetic peptide molecule AEM-28 and its analogs. Its development activities represent a single operating segment as they shared the same product development path and utilized the same company resources. The biotechnology companies and public institutions compete with the Company in recruiting for research personnel and subjects, which affect its ability to complete research studies.

Ratios

vs
industry
vs
history
P/B 22.50
CAPS's P/B is ranked lower than
99.99% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. CAPS: 22.50 )
Ranked among companies with meaningful P/B only.
CAPS' s P/B Range Over the Past 10 Years
Min: 0.04  Med: 0.23 Max: 5.75
Current: 22.5
0.04
5.75
Current Ratio 3.55
CAPS's Current Ratio is ranked lower than
99.99% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. CAPS: 3.55 )
Ranked among companies with meaningful Current Ratio only.
CAPS' s Current Ratio Range Over the Past 10 Years
Min: 2.57  Med: 15.68 Max: 140.04
Current: 3.55
2.57
140.04
Quick Ratio 3.55
CAPS's Quick Ratio is ranked lower than
99.99% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. CAPS: 3.55 )
Ranked among companies with meaningful Quick Ratio only.
CAPS' s Quick Ratio Range Over the Past 10 Years
Min: 1.8  Med: 15.68 Max: 140.04
Current: 3.55
1.8
140.04

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -65.66
CAPS's Earnings Yield (Greenblatt) (%) is ranked lower than
99.99% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. CAPS: -65.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CAPS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -119.9  Med: 22.50 Max: 33715.6
Current: -65.66
-119.9
33715.6

More Statistics

EPS (TTM) $ -0.06
Short Percentage of Float0.08%
52-Week Range $0.07 - 0.25
Shares Outstanding (Mil)40.89
» More Articles for CAPS

Headlines

Articles On GuruFocus.com
Orthologic Corp. Reports Operating Results (10-Q) Nov 10 2010 
Orthologic Corp. Reports Operating Results (10-Q) Aug 09 2010 
Orthologic Corp. Reports Operating Results (10-Q) Nov 09 2009 
Orthologic Corp. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
CAPSTONE THERAPEUTICS CORP. Financials May 21 2016
CAPSTONE THERAPEUTICS CORP. Files SEC form 10-Q, Quarterly Report May 13 2016
CAPSTONE THERAPEUTICS CORP. Files SEC form 10-K, Annual Report Mar 30 2016
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Change in Directors or Principal Officers Mar 18 2016
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Changes in Registrant's Certifying Accountant,... Mar 04 2016
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Results of Operations and Financial Condition Feb 11 2016
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Creation of a Direct Financial Obligation or an... Feb 03 2016
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Creation of a Direct Financial Obligation or an... Dec 15 2015
CAPSTONE THERAPEUTICS CORP. Files SEC form 10-Q, Quarterly Report Nov 09 2015
Edited Transcript of CAPS earnings conference call or presentation 13-Aug-15 8:30pm GMT Aug 17 2015
CAPSTONE THERAPEUTICS CORP. Files SEC form 10-Q, Quarterly Report Aug 13 2015
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 13 2015
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jul 23 2015
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 22 2015
CAPSTONE THERAPEUTICS CORP. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jun 02 2015
CAPSTONE THERAPEUTICS CORP. Files SEC form 10-Q, Quarterly Report May 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)